Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Cancer Research and Treatment|December 8, 2015
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder CancerVivek Narayan, Ronac Mamtani, Stephen Keefe, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 19, 2016
Innovation in Bladder Cancer ImmunotherapyH Barton Grossman, Donald L Lamm, Ashish M Kamat, et al.American Journal of Clinical Oncology|September 11, 2019
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin IneligibleTomoko Freshwater, Haojie Li, Chandni Valiathan, et al.Cancer Biology & Therapy|October 24, 2007
Childhood ALL and second neoplasmsTapan N Maniar, Inbal Braunstein, Stephen Keefe, et al.European Urology Oncology|August 15, 2019
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based TherapyKarl Patterson, Vimalanand Prabhu, Ruifeng Xu, et al.Cancer Science|February 4, 2020
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100Shin Nishio, Koji Matsumoto, Kazuhiro Takehara, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2017
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell CarcinomaVivek Narayan, Stephen Keefe, Naomi Haas, et al.Circulation. Heart Failure|April 18, 2018
Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell CarcinomaAnna B Catino, Rebecca A Hubbard, Julio A Chirinos, et al.The New England Journal of Medicine|January 19, 2022
Lenvatinib plus Pembrolizumab for Advanced Endometrial CancerVicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.Pageof 1